#Followings are the three methods performed by different school of thoughts:1)Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function..
#(S1 (S (NP (NNS Followings)) (VP (AUX are) (NP (NP (DT the) (CD three) (NNS methods)) (VP (VBN performed) (PP (IN by) (NP (JJ different) (NN school)))) (PP (IN of) (NP (NP (CD thoughts:1) (-RRB- -RRB-) (JJ Pulmonary) (NN vein) (NN isolation)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ atrial) (NN fibrillation)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN impaired) (JJ systolic) (NN function))))))))))) (. .))) (. .)))
#Rule:Nouns
r1FollowingsNNS
r1methodsNNS
r1schoolNN
r1Pulmonary veinPersonAnnotation
r1isolationNN
r1treatmentNN
r1fibrillationNN
r1patientsNNS
r1functionNN

#Rule:Verbs
r2performedVBN
r2impairedVBN

#Rule:Adjs
r4differentJJ
r4atrialOrganizationAnnotation
r4systolicJJ

#Rule:Adj-Noun
r5threeCDmethodsNNS
r5differentJJschoolNN
r5thoughts:1CDisolationNN
r5Pulmonary veinPersonAnnotationisolationNN
r5atrialOrganizationAnnotationfibrillationNN
r5impairedVBNfunctionNN
r5systolicJJfunctionNN

#Rule:HeadNoun-V
r11FollowingsNNSareAUX

#Rule:V-By-Agent
r13schoolNNperformedVBN

#Rule:V-HeadNoun
r21areAUXmethodsNNS

#Rule:V-HeadNoun(passive)
r24performedVBNmethodsNNS

#Rule:PPinNP
r26methodsNNSofINisolationNN
r26isolationNNforINtreatmentNN
r26treatmentNNofINfibrillationNN
r26fibrillationNNinINpatientsNNS
r26patientsNNSwithINfunctionNN

#Rule:IS-RULE
r47methodsNNSFollowingsNNS

#OBJECTIVES: We aimed to determine the safety and efficacy of pulmonary vein isolation (PVI) in atrial fibrillation (AF) patients with impaired left ventricular (LV) systolic function..
#(S1 (FRAG (NP (NNS OBJECTIVES)) (: :) (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (JJ pulmonary) (NN vein) (NN isolation)) (PRN (-LRB- -LRB-) (NP (NNP PVI)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (JJ atrial) (NN fibrillation) (PRN (-LRB- -LRB-) (NN AF) (-RRB- -RRB-)) (NNS patients)) (PP (IN with) (NP (VBN impaired) (JJ left) (JJ ventricular) (PRN (-LRB- -LRB-) (NP (NNP LV)) (-RRB- -RRB-)) (JJ systolic) (NN function))))))))) (. .)) (. .)))
#Rule:Nouns
r1OBJECTIVESNNS
r1safetyNN
r1efficacyNN
r1veinPersonAnnotation
r1isolationNN
r1PVILocationAnnotation
r1fibrillationNN
r1AFOrganizationAnnotation
r1patientsNNS
r1LVLocationAnnotation
r1functionNN

#Rule:Verbs
r2aimedVBD
r2determineVB
r2impairedVBN

#Rule:Adjs
r4pulmonaryJJ
r4atrialJJ
r4leftJJ
r4ventricularJJ
r4systolicJJ

#Rule:Adj-Noun
r5pulmonaryJJisolationNN
r5atrialJJpatientsNNS
r5impairedVBNfunctionNN
r5leftJJfunctionNN
r5ventricularJJfunctionNN
r5systolicJJfunctionNN

#Rule:N-HeadNoun
r8veinPersonAnnotationisolationNN

#Rule:HeadNoun-V
r11wePRPaimedVBD

#Rule:V-HeadNoun
r21determineVBsafetyNN

#Rule:PPinNP
r26safetyNNofINisolationNN
r26patientsNNSwithINfunctionNN

#Rule:PPinVP
r30determineVBinINpatientsNNS

#Rule:V-V
r44aimedVBDdetermineVB

#BACKGROUND: To date, PVI has been performed primarily in patients with normal LV function. Yet, many AF patients have impaired LV systolic function. The outcomes of PVI in patients with impaired LV systolic function are unknown..
#(S1 (NP (NP (NN BACKGROUND)) (: :) (S (PP (TO To) (NP (NN date))) (, ,) (S (NP (NNP PVI)) (VP (AUX has) (VP (AUX been) (VP (VBN performed) (ADVP (RB primarily)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ normal) (NN LV) (NNS function.))))) (ADVP (RB Yet)))))) (, ,) (S (NP (JJ many) (NNP AF) (NNS patients)) (VP (AUX have) (VP (VBN impaired) (NP (CD LV) (JJ systolic) (NNS function.)) (NP (NP (DT The) (NNS outcomes)) (PP (IN of) (NP (NNP PVI)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (VBN impaired) (NNS LV)) (SBAR (S (NP (JJ systolic) (NN function)) (VP (AUX are) (ADJP (JJ unknown)))))))))))) (. .)) (. .)))
#Rule:Nouns
r1BACKGROUNDNN
r1dateNN
r1PVIOrganizationAnnotation
r1patientsNNS
r1LVNN
r1functionNNS
r1AFOrganizationAnnotation
r1patientsNNS
r1functionNNS
r1outcomesNNS
r1PVIOrganizationAnnotation
r1patientsNNS
r1LVNNS
r1functionNN

#Rule:Verbs
r2performedVBN
r2impairedVBN
r2impairedVBN

#Rule:Adjs
r4normalJJ
r4manyJJ
r4systolicJJ
r4systolicJJ
r4unknownJJ

#Rule:Adj-Noun
r5normalJJfunctionNNS
r5manyJJpatientsNNS
r5LVCDfunctionNNS
r5systolicJJfunctionNNS
r5impairedVBNLVNNS
r5systolicJJfunctionNN

#Rule:N-HeadNoun
r8LVNNfunctionNNS
r8AFOrganizationAnnotationpatientsNNS

#Rule:HeadNoun-V
r11functionNNareAUX

#Rule:HeadNoun-V
r12patientsNNSimpairedVBN

#Rule:V-HeadNoun
r21impairedVBNfunctionNNS
r21impairedVBNoutcomesNNS

#Rule:V-HeadNoun(passive)
r23performedVBNPVIOrganizationAnnotation

#Rule:V-ADJ
r25areAUXunknownJJ

#Rule:PPinNP
r26patientsNNSwithINfunctionNNS
r26outcomesNNSofINPVIOrganizationAnnotation
r26patientsNNSwithINLVNNS

#Rule:PPinVP
r32performedVBNinINpatientsNNS
r32impairedVBNinINpatientsNNS

#Rule:PPinS
r36hasAUXtoTOdateNN

#Rule:V-ADV
r46performedVBNprimarilyRB
r46performedVBNYetPersonAnnotation

#METHODS: We included 377 consecutive patients undergoing PVI between December 2000 and January 2003.
#(S1 (FRAG (NP (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD included) (NP (NP (CD 377) (JJ consecutive) (NNS patients)) (VP (VBG undergoing) (NP (NNP PVI)) (PP (IN between) (NP (NP (NNP December) (CD 2000)) (CC and) (NP (NNP January) (CD 2003)))))))) (. .)))
#Rule:Nouns
r1METHODSNNS
r1patientsNNS
r1PVIOrganizationAnnotation
r1DecemberNNP
r1JanuaryNNP

#Rule:Verbs
r2includedVBD
r2undergoingVBG

#Rule:Adjs
r4consecutiveJJ

#Rule:Adj-Noun
r5377CDpatientsNNS
r5consecutiveJJpatientsNNS
r52000CDDecemberNNP
r52003CDJanuaryNNP

#Rule:HeadNoun-V
r11wePRPincludedVBD
r11patientsNNSundergoingVBG

#Rule:V-HeadNoun
r21includedVBDpatientsNNS
r21undergoingVBGPVIOrganizationAnnotation

#Rule:PPinVP
r30undergoingVBGbetweenINDecemberNNP
r30undergoingVBGbetweenINJanuaryNNP

# Ninety-four patients had impaired LV function (ejection fraction [EF]<40%), and they comprised the study group.
#(S1 (S (S (NP (JJ Ninety-four) (NNS patients)) (VP (AUX had) (NP (NP (VBN impaired) (JJ LV) (NN function)) (PRN (-LRB- -LRB-) (NP (NP (NN ejection) (NN fraction) (NN [EF) (NNS -RSB-)) (NP (CD <40) (NN %))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (PRP they)) (VP (VBN comprised) (NP (DT the) (NN study) (NN group)))) (. .)))
#Rule:Nouns
r1patientsNNS
r1functionNN
r1ejectionNN
r1fractionNN
r1[EF]LocationAnnotation
r1%NN
r1studyNN
r1groupNN

#Rule:Verbs
r2impairedVBN
r2comprisedVBN

#Rule:Adjs
r4Ninety-fourJJ
r4LVJJ

#Rule:Adj-Noun
r5Ninety-fourJJpatientsNNS
r5impairedVBNfunctionNN
r5LVJJfunctionNN
r5<40CD%NN

#Rule:N-HeadNoun
r8fractionNN[EF]LocationAnnotation
r8ejectionNN[EF]LocationAnnotation
r8studyNNgroupNN

#Rule:HeadNoun-V
r11patientsNNShadAUX

#Rule:V-HeadNoun
r21hadAUXfunctionNN
r21comprisedVBNgroupNN

#Rule:V-HeadNoun(passive)
r24comprisedVBNtheyPRP

# The control group was the remaining 283 patients who had a normal EF.
#(S1 (S (NP (DT The) (NN control) (NN group)) (VP (AUX was) (NP (NP (DT the) (VBG remaining) (CD 283) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT a) (JJ normal) (NN EF))))))) (. .)))
#Rule:Nouns
r1controlNN
r1groupNN
r1patientsNNS
r1EFNN

#Rule:Verbs
r2remainingVBG

#Rule:Adjs
r4normalJJ

#Rule:Adj-Noun
r5remainingVBGpatientsNNS
r5283CDpatientsNNS
r5normalJJEFNN

#Rule:N-HeadNoun
r8controlNNgroupNN

#Rule:HeadNoun-V
r11groupNNwasAUX

#Rule:HeadNoun-(who/that)-V
r14patientsNNShadAUX

#Rule:V-HeadNoun
r21wasAUXpatientsNNS
r21hadAUXEFNN

#Rule:IS-RULE
r47patientsNNSgroupNN

# End points included AF recurrence and changes in EF and quality of life (QoL).
#(S1 (S (NP (NN End) (NNS points)) (VP (VBD included) (NP (NP (JJ AF) (NN recurrence)) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN EF) (CC and) (NN quality)) (PP (IN of) (NP (NP (NN life)) (PRN (-LRB- -LRB-) (NP (NNP QoL)) (-RRB- -RRB-))))))))) (. .)))
#Rule:Nouns
r1EndNN
r1pointsNNS
r1recurrenceNN
r1changesNNS
r1EFLocationAnnotation
r1qualityNN
r1lifeNN
r1QoLLocationAnnotation

#Rule:Verbs
r2includedVBD

#Rule:Adjs
r4AFOrganizationAnnotation

#Rule:Adj-Noun
r5AFOrganizationAnnotationrecurrenceNN

#Rule:N-HeadNoun
r8EndNNpointsNNS

#Rule:HeadNoun-V
r11pointsNNSincludedVBD

#Rule:V-HeadNoun
r21includedVBDrecurrenceNN

#Rule:PPinNP
r26changesNNSinINEFLocationAnnotation
r26EFLocationAnnotationofINlifeNN

#RESULTS: Mean EF was 36% in our study group, compared with 54% in controls.
#(S1 (NP (NP (NNS RESULTS)) (: :) (S (NP (JJ Mean) (NN EF)) (VP (AUX was) (NP (NP (CD 36) (NN %)) (PP (IN in) (NP (PRP$ our) (NN study) (NN group)))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 54) (NN %)) (PP (IN in) (NP (NNS controls)))))))) (. .)))
#Rule:Nouns
r1RESULTSNNS
r1Mean EFOrganizationAnnotation
r1%NN
r1studyNN
r1groupNN
r1%NN
r1controlsNNS

#Rule:Verbs
r2comparedVBN

#Rule:Adj-Noun
r536CD%NN
r554CD%NN

#Rule:PRP-Noun
r6ourPRP$groupNN

#Rule:N-HeadNoun
r8studyNNgroupNN

#Rule:HeadNoun-V
r11Mean EFOrganizationAnnotationwasAUX

#Rule:V-HeadNoun
r21wasAUX%NN

#Rule:PPinNP
r26%NNinINgroupNN
r26%NNinINcontrolsNNS

#Rule:IS-RULE
r47%NNMean EFOrganizationAnnotation

# After initial PVI, 73% of patients with impaired EF and 87% of patients with normal EF were free of AF recurrence at 14 ?? 6 months (p = 0.03).
#(S1 (S (PP (IN After) (NP (JJ initial) (NNP PVI))) (, ,) (NP (NP (NP (CD 73) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN impaired) (NNS EF)))))) (CC and) (NP (NP (CD 87) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ normal) (NNS EF))))))) (VP (AUX were) (ADJP (JJ free) (PP (IN of) (NP (NP (NP (NP (CD AF) (NN recurrence)) (PP (IN at) (NP (CD 14)) (. ?) (. ?))) (NP (CD 6) (NNS months))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.03)) (-RRB- -RRB-)))))) (. .)))
#Rule:Nouns
r1PVIOrganizationAnnotation
r1%NN
r1patientsNNS
r1EFPersonAnnotation
r1%NN
r1patientsNNS
r1EFNNS
r1recurrenceNN
r1monthsNNS
r1pNNP

#Rule:Verbs
r2impairedVBN

#Rule:Adjs
r4initialJJ
r4normalJJ
r4freeJJ

#Rule:Adj-Noun
r5initialJJPVIOrganizationAnnotation
r573CD%NN
r5impairedVBNEFPersonAnnotation
r587CD%NN
r5normalJJEFNNS
r5AFOrganizationAnnotationrecurrenceNN
r56CDmonthsNNS
r50.03CDpNNP

#Rule:HeadNoun-V
r11%NNwereAUX
r11%NNwereAUX

#Rule:V-ADJ
r25wereAUXfreeJJ

#Rule:PPinNP
r26%NNofINpatientsNNS
r26patientsNNSwithINEFPersonAnnotation
r26%NNofINpatientsNNS
r26patientsNNSwithINEFNNS
r26recurrenceNNatIN14CD

#Rule:PPinS
r36wereAUXafterINPVIOrganizationAnnotation

#Rule:PPinADJP
r37freeJJofINrecurrenceNN
r37freeJJofINmonthsNNS

# In the study group, there was a nonsignificant increase in EF of 4.6% and significant improvement in QoL.
#(S1 (S (PP (IN In) (NP (DT the) (NN study) (NN group))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (NP (DT a) (JJ nonsignificant) (NN increase)) (PP (IN in) (NP (NP (NNS EF)) (PP (IN of) (NP (CD 4.6) (NN %)))))) (CC and) (NP (NP (JJ significant) (NN improvement)) (PP (IN in) (NP (NNP QoL)))))) (. .)))
#Rule:Nouns
r1studyNN
r1groupNN
r1increaseNN
r1EFNNS
r1%NN
r1improvementNN
r1QoLLocationAnnotation

#Rule:Adjs
r4nonsignificantJJ
r4significantJJ

#Rule:Adj-Noun
r5nonsignificantJJincreaseNN
r54.6CD%NN
r5significantJJimprovementNN

#Rule:N-HeadNoun
r8studyNNgroupNN

#Rule:HeadNoun-V
r11thereEXwasAUX

#Rule:V-HeadNoun
r21wasAUXincreaseNN

#Rule:PPinNP
r26increaseNNinINEFNNS
r26EFNNSofIN%NN
r26improvementNNinINQoLLocationAnnotation

#Rule:PPinS
r36wasAUXinINgroupNN

# Complication rates were low and included a 1% risk of pulmonary vein stenosis..CON
#(S1 (S (NP (NN Complication) (NNS rates)) (VP (VP (AUX were) (ADJP (JJ low))) (CC and) (VP (VBD included) (NP (NP (DT a) (ADJP (CD 1) (NN %)) (NN risk)) (PP (IN of) (NP (JJ pulmonary) (NN vein) (NNS stenosis)))) (NP (CD ..) (NN CON))))))
#Rule:Nouns
r1ComplicationNN
r1ratesNNS
r1%NN
r1riskNN
r1veinPersonAnnotation
r1stenosisNNS
r1CONCLUSIONSOrganizationAnnotation

#Rule:Verbs
r2includedVBD

#Rule:Adjs
r4lowJJ
r4pulmonaryJJ

#Rule:Adj-Noun
r51CDriskNN
r5pulmonaryJJstenosisNNS
r5..CDCONCLUSIONSOrganizationAnnotation

#Rule:N-HeadNoun
r8ComplicationNNratesNNS
r8veinPersonAnnotationstenosisNNS

#Rule:HeadNoun-V
r11ratesNNSincludedVBD
r11ratesNNSwereAUX

#Rule:V-HeadNoun
r21includedVBDriskNN
r21includedVBDCONCLUSIONSOrganizationAnnotation

#Rule:V-ADJ
r25wereAUXlowJJ

#Rule:PPinNP
r26riskNNofINstenosisNNS

#CONCLUSIONS: Although the AF recurrence rate after initial PVI in impaired EF patients was higher than in normal EF subjects, nearly three-fourths of patients with impaired EF remained AF-free.
#(S1 (S (NP (NNS CONCLUSIONS)) (: :) (SBAR (IN Although) (S (NP (NP (DT the) (ADJP (CD AF) (NN recurrence)) (NN rate)) (PP (IN after) (NP (JJ initial) (NNP PVI))) (PP (IN in) (NP (VBN impaired) (NN EF) (NNS patients)))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN in) (NP (JJ normal) (NN EF) (NNS subjects)))))))) (, ,) (NP (NP (RB nearly) (JJ three-fourths)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN impaired) (NNS EF)))))) (VP (VBD remained) (ADJP (JJ AF-free))) (. .)))
#Rule:Nouns
r1CONCLUSIONSOrganizationAnnotation
r1recurrenceNN
r1rateNN
r1PVINNP
r1EFNN
r1patientsNNS
r1EFNN
r1subjectsNNS
r1patientsNNS
r1EFNNS

#Rule:Verbs
r2impairedVBN
r2impairedVBN
r2remainedVBD

#Rule:Adjs
r4initialJJ
r4higherJJR
r4normalJJ
r4three-fourthsJJ
r4AF-freeJJ

#Rule:Adj-Noun
r5AFOrganizationAnnotationrateNN
r5initialJJPVINNP
r5impairedVBNpatientsNNS
r5normalJJsubjectsNNS
r5impairedVBNEFNNS

#Rule:N-HeadNoun
r8EFNNpatientsNNS
r8EFNNsubjectsNNS

#Rule:HeadNoun-V
r11CONCLUSIONSOrganizationAnnotationremainedVBD
r11three-fourthsJJremainedVBD
r11rateNNwasAUX

#Rule:V-ADJ
r25wasAUXhigherJJR

#Rule:PPinNP
r26rateNNafterINPVINNP
r26rateNNinINpatientsNNS
r26three-fourthsJJofINpatientsNNS
r26patientsNNSwithINEFNNS

# Although our sample size was nonrandomized, our results suggest PVI may be a feasible therapeutic option in AF patients with impaired EF.
#(S1 (S (SBAR (IN Although) (S (NP (PRP$ our) (NN sample) (NN size)) (VP (AUX was) (VP (VBN nonrandomized))))) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP suggest) (SBAR (S (NP (NNP PVI)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ feasible) (JJ therapeutic) (NN option)) (PP (IN in) (NP (NP (JJ AF) (NNS patients)) (PP (IN with) (NP (VBN impaired) (NNS EF))))))))))) (. .)))
#Rule:Nouns
r1sampleNN
r1sizeNN
r1resultsNNS
r1PVINNP
r1optionNN
r1patientsNNS
r1EFPersonAnnotation

#Rule:Verbs
r2nonrandomizedVBN
r2suggestVBP
r2impairedVBN

#Rule:Adjs
r4feasibleJJ
r4therapeuticJJ
r4AFOrganizationAnnotation

#Rule:Adj-Noun
r5feasibleJJoptionNN
r5therapeuticJJoptionNN
r5AFOrganizationAnnotationpatientsNNS
r5impairedVBNEFPersonAnnotation

#Rule:PRP-Noun
r6ourPRP$sizeNN
r6ourPRP$resultsNNS

#Rule:N-HeadNoun
r8sampleNNsizeNN

#Rule:HeadNoun-V
r11resultsNNSsuggestVBP
r11PVINNPbeAUX

#Rule:V-HeadNoun
r21beAUXoptionNN

#Rule:V-HeadNoun(passive)
r23nonrandomizedVBNsizeNN

#Rule:PPinNP
r26optionNNinINpatientsNNS
r26patientsNNSwithINEFPersonAnnotation

#Rule:IS-RULE
r47optionNNPVINNP

# Randomized studies with more patients and longer follow-up are warranted.2)Catheter Ablation of Atrial Fibrillation.
#(S1 (S (NP (NP (JJ Randomized) (NNS studies)) (PP (IN with) (UCP (NP (JJR more) (NNS patients)) (CC and) (ADVP (RBR longer) (JJ follow-up))))) (VP (AUX are) (NP (NP (CD warranted.2) (-RRB- -RRB-) (NN Catheter) (NN Ablation)) (PP (IN of) (NP (NNP Atrial) (NNP Fibrillation))))) (. .)))
#Rule:Nouns
r1studiesNNS
r1patientsNNS
r1Catheter Ablation of Atrial FibrillationOrganizationAnnotation

#Rule:Adjs
r4RandomizedJJ
r4moreJJR
r4follow-upJJ

#Rule:Adj-Noun
r5RandomizedJJstudiesNNS
r5moreJJRpatientsNNS
r5warranted.2CDCatheter Ablation of Atrial FibrillationOrganizationAnnotation

#Rule:HeadNoun-V
r11studiesNNSareAUX

#Rule:V-HeadNoun
r21areAUXCatheter Ablation of Atrial FibrillationOrganizationAnnotation

#Rule:IS-RULE
r47Catheter Ablation of Atrial FibrillationOrganizationAnnotationstudiesNNS

# A 74-year-old man with atrial fibrillation (AF) underwent electrophysiologic study and catheter ablation with a noncontact mapping system.
#(S1 (S (NP (NP (DT A) (JJ 74-year-old) (NN man)) (PP (IN with) (NP (JJ atrial) (NN fibrillation) (PRN (-LRB- -LRB-) (NNP AF) (-RRB- -RRB-))))) (VP (VBD underwent) (NP (NP (JJ electrophysiologic) (NN study)) (CC and) (NP (NN catheter) (NN ablation))) (PP (IN with) (NP (DT a) (JJ noncontact) (NN mapping) (NN system)))) (. .)))
#Rule:Nouns
r1manNN
r1atrial fibrillation (AFOrganizationAnnotation
r1studyNN
r1catheterNN
r1ablationNN
r1mappingNN
r1systemNN

#Rule:Verbs
r2underwentVBD

#Rule:Adjs
r474-year-oldJJ
r4electrophysiologicJJ
r4noncontactJJ

#Rule:Adj-Noun
r574-year-oldJJmanNN
r5electrophysiologicJJstudyNN
r5noncontactJJsystemNN

#Rule:N-HeadNoun
r8catheterNNablationNN
r8mappingNNsystemNN

#Rule:HeadNoun-V
r11manNNunderwentVBD

#Rule:V-HeadNoun
r21underwentVBDstudyNN

#Rule:PPinNP
r26manNNwithINatrial fibrillation (AFOrganizationAnnotation

#Rule:PPinVP
r30underwentVBDwithINsystemNN

# AF was induced by coronary sinus pacing, and noncontact mapping showed ever-changing movement of multiple wavefronts with one dominant reentrant circuit around the tricuspid annulus, splitting wavefront conduction through the gaps in the crista terminalis, and then fusion and stasis of wavefronts.
#(S1 (S (S (NP (NNP AF)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (JJ coronary) (JJ sinus) (NN pacing)))))) (, ,) (CC and) (S (NP (JJ noncontact) (NN mapping)) (VP (VBD showed) (NP (NP (NP (JJ ever-changing) (NN movement)) (PP (IN of) (NP (NP (JJ multiple) (NNS wavefronts)) (PP (IN with) (NP (NP (CD one) (JJ dominant) (NN reentrant) (NN circuit)) (PP (IN around) (NP (DT the) (JJ tricuspid) (NN annulus)))))))) (, ,) (NP (NP (JJ splitting) (NN wavefront) (NN conduction)) (PP (IN through) (NP (NP (DT the) (NNS gaps)) (PP (IN in) (NP (DT the) (JJ crista) (NN terminalis)))))) (, ,) (CC and) (ADVP (RB then)) (NP (NP (NN fusion) (CC and) (NN stasis)) (PP (IN of) (NP (NNS wavefronts))))))) (. .)))
#Rule:Nouns
r1AFOrganizationAnnotation
r1pacingNN
r1mappingNN
r1movementNN
r1wavefrontsNNS
r1reentrantNN
r1circuitNN
r1annulusNN
r1wavefrontNN
r1conductionNN
r1gapsNNS
r1terminalisNN
r1fusionNN
r1stasisNN
r1wavefrontsNNS

#Rule:Verbs
r2inducedVBN
r2showedVBD

#Rule:Adjs
r4coronaryJJ
r4sinusJJ
r4noncontactJJ
r4ever-changingJJ
r4multipleJJ
r4dominantJJ
r4tricuspidJJ
r4splittingJJ
r4cristaJJ

#Rule:Adj-Noun
r5coronaryJJpacingNN
r5sinusJJpacingNN
r5noncontactJJmappingNN
r5ever-changingJJmovementNN
r5multipleJJwavefrontsNNS
r5oneCDcircuitNN
r5dominantJJcircuitNN
r5tricuspidJJannulusNN
r5splittingJJconductionNN
r5cristaJJterminalisNN

#Rule:N-HeadNoun
r8reentrantNNcircuitNN
r8wavefrontNNconductionNN

#Rule:N-ApposN
r10movementNNconductionNN

#Rule:HeadNoun-V
r11mappingNNshowedVBD

#Rule:V-By-Agent
r13pacingNNinducedVBN

#Rule:V-HeadNoun
r21showedVBDmovementNN

#Rule:V-HeadNoun(passive)
r23inducedVBNAFOrganizationAnnotation

#Rule:PPinNP
r26movementNNofINwavefrontsNNS
r26wavefrontsNNSwithINcircuitNN
r26circuitNNaroundINannulusNN
r26conductionNNthroughINgapsNNS
r26gapsNNSinINterminalisNN
r26fusionNNofINwavefrontsNNS

# After creation of bidirectional conduction block over crista terminalis gaps and the cavotricuspid isthmus, AF or atrial flutter was noninducible.
#(S1 (S (PP (IN After) (NP (NP (NN creation)) (PP (IN of) (NP (NP (JJ bidirectional) (NN conduction) (NN block)) (PP (IN over) (NP (NP (JJ crista) (NN terminalis) (NNS gaps)) (CC and) (NP (DT the) (JJ cavotricuspid) (NN isthmus)))))))) (, ,) (NP (ADJP (JJ AF) (CC or) (JJ atrial)) (NN flutter)) (VP (AUX was) (ADJP (JJ noninducible))) (. .)))
#Rule:Nouns
r1creationNN
r1conductionNN
r1blockNN
r1terminalisNN
r1gapsNNS
r1cavotricuspid isthmusPersonAnnotation
r1flutterNN

#Rule:Adjs
r4bidirectionalJJ
r4cristaJJ
r4AFOrganizationAnnotation
r4atrialJJ
r4noninducibleJJ

#Rule:Adj-Noun
r5bidirectionalJJblockNN
r5cristaJJgapsNNS
r5AFOrganizationAnnotationflutterNN
r5atrialJJflutterNN

#Rule:N-HeadNoun
r8conductionNNblockNN
r8terminalisNNgapsNNS

#Rule:HeadNoun-V
r11flutterNNwasAUX

#Rule:V-ADJ
r25wasAUXnoninducibleJJ

#Rule:PPinNP
r26creationNNofINblockNN
r26blockNNoverINgapsNNS
r26blockNNoverINcavotricuspid isthmusPersonAnnotation

#Rule:PPinS
r36wasAUXafterINcreationNN

# No further AF recurrence was noted during 6-month follow-up.3)Irrigated-Tip Catheter Ablation of PVs.
#(S1 (S (NP (DT No) (JJ further) (NN AF) (NN recurrence)) (VP (AUX was) (VP (VBN noted) (PP (IN during) (NP (NP (ADJP (JJ 6-month) (NP (CD follow-up.3)) (-RRB- -RRB-)) (JJ Irrigated-Tip) (NN Catheter) (NN Ablation)) (PP (IN of) (NP (NNS PVs))))))) (. .)))
#Rule:Nouns
r1AFOrganizationAnnotation
r1recurrenceNN
r1TipOrganizationAnnotation

#Rule:Verbs
r2notedVBN

#Rule:Adjs
r4furtherJJ
r46-monthJJ
r4Irrigated-TipJJ

#Rule:Adj-Noun
r5furtherJJrecurrenceNN
r56-monthJJTipOrganizationAnnotation
r5Irrigated-TipJJTipOrganizationAnnotation

#Rule:N-HeadNoun
r8AFOrganizationAnnotationrecurrenceNN

#Rule:V-HeadNoun(passive)
r23notedVBNrecurrenceNN

#Rule:PPinVP
r32notedVBNduringINTipOrganizationAnnotation

# Introduction: Catheter ablation of pulmonary veins (PV) for treatment of atrial fibrillation (AF) is limited by the disparate requirements of sufficient energy delivery to achieve PV isolation while avoiding PV stenosis.
#(S1 (FRAG (NP (NN Introduction)) (: :) (S (NP (NP (NN Catheter) (NN ablation)) (PP (IN of) (NP (JJ pulmonary) (NNS veins))) (PRN (-LRB- -LRB-) (NP (NNP PV)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ atrial) (NN fibrillation) (PRN (-LRB- -LRB-) (NNP AF) (-RRB- -RRB-))))))) (VP (AUX is) (VP (VBN limited) (PP (IN by) (NP (NP (DT the) (JJ disparate) (NNS requirements)) (PP (IN of) (NP (NP (JJ sufficient) (NN energy) (NN delivery)) (SBAR (S (VP (TO to) (VP (VB achieve) (NP (CD PV) (NN isolation)) (SBAR (IN while) (S (VP (VBG avoiding) (NP (CD PV) (NN stenosis)))))))))))))))) (. .)))
#Rule:Nouns
r1IntroductionNN
r1CatheterPersonAnnotation
r1ablationNN
r1veinsPersonAnnotation
r1PVLocationAnnotation
r1treatmentNN
r1atrial fibrillationOrganizationAnnotation
r1AFOrganizationAnnotation
r1requirementsNNS
r1energyNN
r1deliveryNN
r1isolationNN
r1stenosisNN

#Rule:Verbs
r2limitedVBN
r2achieveVB
r2avoidingVBG

#Rule:Adjs
r4pulmonaryJJ
r4disparateJJ
r4sufficientJJ

#Rule:Adj-Noun
r5pulmonaryJJveinsPersonAnnotation
r5disparateJJrequirementsNNS
r5sufficientJJdeliveryNN
r5PVCDisolationNN
r5PVCDstenosisNN

#Rule:N-HeadNoun
r8CatheterPersonAnnotationablationNN
r8energyNNdeliveryNN

#Rule:V-By-Agent
r13requirementsNNSlimitedVBN

#Rule:HeadNoun-(who/that)-V
r14deliveryNNachieveVB

#Rule:V-HeadNoun
r21achieveVBisolationNN
r21avoidingVBGstenosisNN

#Rule:V-HeadNoun(passive)
r23limitedVBNablationNN

#Rule:PPinNP
r26ablationNNofINveinsPersonAnnotation
r26ablationNNforINtreatmentNN
r26treatmentNNofINatrial fibrillationOrganizationAnnotation
r26requirementsNNSofINdeliveryNN

#Rule:V-IN-V
r43achieveVBwhileINavoidingVBG

# The aim of the present study was to evaluate the safety and efficacy of using an irrigated-tip catheter for systematic isolation of PV.
#(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (S (VP (VBG using) (NP (DT an) (JJ irrigated-tip) (NN catheter)) (PP (IN for) (NP (NP (JJ systematic) (NN isolation)) (PP (IN of) (NP (NNP PV))))))))))))) (. .)))
#Rule:Nouns
r1aimNN
r1studyNN
r1safetyNN
r1efficacyNN
r1catheterNN
r1isolationNN
r1PVOrganizationAnnotation

#Rule:Verbs
r2evaluateVB
r2usingVBG

#Rule:Adjs
r4presentJJ
r4irrigated-tipJJ
r4systematicJJ

#Rule:Adj-Noun
r5presentJJstudyNN
r5irrigated-tipJJcatheterNN
r5systematicJJisolationNN

#Rule:HeadNoun-V
r11aimNNwasAUX

#Rule:V-HeadNoun
r21evaluateVBsafetyNN
r21usingVBGcatheterNN

#Rule:PPinNP
r26aimNNofINstudyNN
r26isolationNNofINPVOrganizationAnnotation

#Rule:PPinVP
r30usingVBGforINisolationNN

#Methods and Results: The study population consisted of 136 consecutive patients (109 men, mean age 52 ?? 10 years) with symptomatic, drug-refractory paroxysmal (122) or persistent (14) AF.
#(S1 (FRAG (NP (NNS Methods) (CC and) (NNS Results)) (: :) (S (NP (DT The) (NN study) (NN population)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 136) (JJ consecutive) (NNS patients)) (PRN (-LRB- -LRB-) (S (NP (CD 109) (NNS men)) (, ,) (VP (VB mean) (NP (NN age) (CD 52))) (. ?)) (. ?) (NP (CD 10) (NNS years)) (-RRB- -RRB-)) (PP (IN with) (NP (JJ symptomatic) (, ,) (ADJP (ADJP (JJ drug-refractory) (JJ paroxysmal)) (PRN (-LRB- -LRB-) (NP (CD 122)) (-RRB- -RRB-)) (CC or) (ADJP (JJ persistent)) (PRN (-LRB- -LRB-) (NP (CD 14)) (-RRB- -RRB-))) (NN AF))))))) (. .)))
#Rule:Nouns
r1MethodsNNS
r1ResultsNNS
r1studyNN
r1populationNN
r1patientsNNS
r1menNNS
r1ageNN
r1yearsNNS
r1AFOrganizationAnnotation

#Rule:Verbs
r2consistedVBD
r2meanVB

#Rule:Adjs
r4consecutiveJJ
r4symptomaticJJ
r4drug-refractoryJJ
r4paroxysmalJJ
r4persistentJJ

#Rule:Adj-Noun
r5136CDpatientsNNS
r5consecutiveJJpatientsNNS
r5109CDmenNNS
r552CDageNN
r510CDyearsNNS
r5symptomaticJJAFOrganizationAnnotation
r5drug-refractoryJJAFOrganizationAnnotation
r5paroxysmalJJAFOrganizationAnnotation
r5persistentJJAFOrganizationAnnotation

#Rule:N-HeadNoun
r8studyNNpopulationNN

#Rule:HeadNoun-V
r11populationNNconsistedVBD
r11menNNSmeanVB

#Rule:V-HeadNoun
r21meanVBageNN

#Rule:PPinNP
r26patientsNNSwithINAFOrganizationAnnotation

#Rule:PPinVP
r30consistedVBDofINpatientsNNS

# Cavotricuspid isthmus ablation and systematic radiofrequency isolation of all four PVs (guided by a circumferential mapping catheter) was performed in all patients with a protocol using an irrigated-tip catheter.
#(S1 (S (NP (NP (NP (JJ Cavotricuspid) (NN isthmus) (NN ablation)) (CC and) (NP (JJ systematic) (NN radiofrequency) (NN isolation))) (PP (IN of) (NP (NP (DT all) (CD four) (NNS PVs)) (PRN (-LRB- -LRB-) (VP (VBN guided) (PP (IN by) (NP (DT a) (JJ circumferential) (NN mapping) (NN catheter)))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (DT all) (NNS patients))) (PP (IN with) (NP (NP (DT a) (NN protocol)) (VP (VBG using) (NP (DT an) (JJ irrigated-tip) (NN catheter))))))) (. .)))
#Rule:Nouns
r1Cavotricuspid isthmusPersonAnnotation
r1ablationNN
r1radiofrequencyNN
r1isolationNN
r1PVsPersonAnnotation
r1mappingNN
r1catheterNN
r1patientsNNS
r1protocolNN
r1catheterPersonAnnotation

#Rule:Verbs
r2guidedVBN
r2performedVBN
r2usingVBG

#Rule:Adjs
r4systematicJJ
r4circumferentialJJ
r4irrigated-tipJJ

#Rule:Adj-Noun
r5Cavotricuspid isthmusPersonAnnotationablationNN
r5systematicJJisolationNN
r5fourCDPVsPersonAnnotation
r5circumferentialJJcatheterNN
r5irrigated-tipJJcatheterPersonAnnotation

#Rule:N-HeadNoun
r8radiofrequencyNNisolationNN
r8mappingNNcatheterNN

#Rule:HeadNoun-V
r11protocolNNusingVBG

#Rule:V-By-Agent
r13catheterNNguidedVBN

#Rule:V-HeadNoun
r21usingVBGcatheterPersonAnnotation

#Rule:V-HeadNoun(passive)
r23performedVBNablationNN
r23performedVBNisolationNN

#Rule:PPinNP
r26ablationNNofINPVsPersonAnnotation

#Rule:PPinVP
r32performedVBNinINpatientsNNS
r32performedVBNwithINprotocolNN

# PV diameter was assessed by selective angiography.
#(S1 (S (NP (JJ PV) (NN diameter)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (JJ selective) (NN angiography))))) (. .)))
#Rule:Nouns
r1PV diameterPersonAnnotation
r1angiographyNN

#Rule:Verbs
r2assessedVBN

#Rule:Adjs
r4selectiveJJ

#Rule:Adj-Noun
r5selectiveJJangiographyNN

#Rule:V-By-Agent
r13angiographyNNassessedVBN

#Rule:V-HeadNoun(passive)
r23assessedVBNPV diameterPersonAnnotation

# The electrophysiologic endpoint of PV isolation was achieved in 100% of patients.
#(S1 (S (NP (NP (DT The) (JJ electrophysiologic) (NN endpoint)) (PP (IN of) (NP (CD PV) (NN isolation)))) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (NP (CD 100) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
#Rule:Nouns
r1endpointNN
r1isolationNN
r1%NN
r1patientsNNS

#Rule:Verbs
r2achievedVBN

#Rule:Adjs
r4electrophysiologicJJ

#Rule:Adj-Noun
r5electrophysiologicJJendpointNN
r5PVOrganizationAnnotationisolationNN
r5100CD%NN

#Rule:V-HeadNoun(passive)
r23achievedVBNendpointNN

#Rule:PPinNP
r26endpointNNofINisolationNN
r26%NNofINpatientsNNS

#Rule:PPinVP
r32achievedVBNinIN%NN

# Bidirectional cavotricuspid isthmus block was achieved in 99% of patients.
#(S1 (S (NP (JJ Bidirectional) (JJ cavotricuspid) (NN isthmus) (NN block)) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (NP (CD 99) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
#Rule:Nouns
r1isthmusPersonAnnotation
r1blockNN
r1%NN
r1patientsNNS

#Rule:Verbs
r2achievedVBN

#Rule:Adjs
r4BidirectionalJJ
r4cavotricuspidJJ

#Rule:Adj-Noun
r5BidirectionalJJblockNN
r5cavotricuspidJJblockNN
r599CD%NN

#Rule:N-HeadNoun
r8isthmusPersonAnnotationblockNN

#Rule:V-HeadNoun(passive)
r23achievedVBNblockNN

#Rule:PPinNP
r26%NNofINpatientsNNS

#Rule:PPinVP
r32achievedVBNinIN%NN

# Moderate PV stenosis (50% narrowing) was observed in one patient (0.7%) without clinical consequence.
#(S1 (S (NP (NP (JJ Moderate) (NN PV) (NN stenosis)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN %)) (NN narrowing)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD one) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 0.7) (NN %)) (-RRB- -RRB-)))) (PP (IN without) (NP (JJ clinical) (NN consequence))))) (. .)))
#Rule:Nouns
r1PV stenosisPersonAnnotation
r1%NN
r1narrowingNN
r1patientNN
r1%NN
r1consequenceNN

#Rule:Verbs
r2observedVBN

#Rule:Adjs
r4ModerateJJ
r4clinicalJJ

#Rule:Adj-Noun
r5ModerateJJPV stenosisPersonAnnotation
r550CD%NN
r5oneCDpatientNN
r50.7CD%NN
r5clinicalJJconsequenceNN

#Rule:V-HeadNoun(passive)
r23observedVBNPV stenosisPersonAnnotation

#Rule:PPinVP
r32observedVBNinINpatientNN
r32observedVBNwithoutINconsequenceNN

# No other complications were observed.
#(S1 (S (NP (DT No) (JJ other) (NNS complications)) (VP (AUX were) (VP (VBN observed))) (. .)))
#Rule:Nouns
r1complicationsNNS

#Rule:Verbs
r2observedVBN

#Rule:Adjs
r4otherJJ

#Rule:Adj-Noun
r5otherJJcomplicationsNNS

#Rule:V-HeadNoun(passive)
r23observedVBNcomplicationsNNS

# Reablation procedures were required in 67 patients (49%).
#(S1 (S (NP (NN Reablation) (NNS procedures)) (VP (AUX were) (VP (VBN required) (PP (IN in) (NP (NP (CD 67) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-)))))) (. .)))
#Rule:Nouns
r1ReablationNN
r1proceduresNNS
r1patientsNNS
r1%NN

#Rule:Verbs
r2requiredVBN

#Rule:Adj-Noun
r567CDpatientsNNS
r549CD%NN

#Rule:N-HeadNoun
r8ReablationNNproceduresNNS

#Rule:V-HeadNoun(passive)
r23requiredVBNproceduresNNS

#Rule:PPinVP
r32requiredVBNinINpatientsNNS

# After a mean follow-up of 8.8 ?? 5.3 months, 81% of patients were free of AF clinical recurrence, including 66% not taking any antiarrhythmic drugs..Con
#(S1 (S (PP (IN After) (NP (NP (DT a) (JJ mean) (NN follow-up)) (PP (IN of) (NP (CD 8.8)))) (. ?) (. ?) (NP (CD 5.3) (NNS months))) (, ,) (NP (NP (CD 81) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (ADJP (JJ free) (PP (IN of) (S (VP (VBG AF) (NP (JJ clinical) (NN recurrence)))))) (, ,) (PP (VBG including) (S (NP (CD 66) (NN %)) (RB not) (VP (VBG taking) (NP (DT any) (JJ antiarrhythmic) (NNS drugs) (NN ..) (NN Con))))))))
#Rule:Nouns
r1follow-upNN
r1monthsNNS
r1%NN
r1patientsNNS
r1recurrenceNN
r1%NN
r1drugsNNS
r1..NN
r1ConOrganizationAnnotation

#Rule:Verbs
r2AFOrganizationAnnotation
r2includingVBG
r2takingVBG

#Rule:Adjs
r4meanJJ
r4freeJJ
r4clinicalJJ
r4antiarrhythmicJJ

#Rule:Adj-Noun
r5meanJJfollow-upNN
r55.3CDmonthsNNS
r581CD%NN
r5clinicalJJrecurrenceNN
r566CD%NN
r5antiarrhythmicJJConOrganizationAnnotation

#Rule:N-HeadNoun
r8..NNConOrganizationAnnotation
r8drugsNNSConOrganizationAnnotation

#Rule:HeadNoun-V
r11%NNwereAUX
r11%NNtakingVBG

#Rule:V-HeadNoun
r21AFOrganizationAnnotationrecurrenceNN
r21takingVBGConOrganizationAnnotation

#Rule:V-ADJ
r25wereAUXfreeJJ

#Rule:PPinNP
r26follow-upNNofIN8.8CD
r26%NNofINpatientsNNS

#Rule:PPinS
r36wereAUXafterINfollow-upNN
r36wereAUXafterINmonthsNNS

#Rule:PPinADJP
r38freeJJofINAFOrganizationAnnotation

#Rule:BE-ADJP-IN-VBG
r51%NNAFOrganizationAnnotation

#Conclusion: Systematic radiofrequency ablation of PV using an irrigated-tip catheter in patients with atrial fibrillation allows complete isolation of all four PVs with a very low incidence of stenosis.
#(S1 (FRAG (NP (NN Conclusion)) (: :) (S (NP (NP (JJ Systematic) (NN radiofrequency) (NN ablation)) (PP (IN of) (NP (NP (NNS PV)) (VP (VBG using) (NP (NP (DT an) (NN irrigated-tip) (NN catheter)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ atrial) (NN fibrillation)))))))))) (VP (VBZ allows) (NP (NP (JJ complete) (NN isolation)) (PP (IN of) (NP (DT all) (CD four) (NNS PVs)))) (PP (IN with) (NP (NP (DT a) (ADJP (RB very) (JJ low)) (NN incidence)) (PP (IN of) (NP (NN stenosis))))))) (. .)))
#Rule:Nouns
r1ConclusionNN
r1radiofrequencyNN
r1ablationNN
r1PVOrganizationAnnotation
r1irrigated-tipNN
r1catheterNN
r1patientsNNS
r1fibrillationNN
r1isolationNN
r1PVsNNS
r1incidenceNN
r1stenosisNN

#Rule:Verbs
r2usingVBG
r2allowsVBZ

#Rule:Adjs
r4SystematicJJ
r4atrialJJ
r4completeJJ
r4lowJJ

#Rule:Adj-Noun
r5SystematicJJablationNN
r5atrialJJfibrillationNN
r5completeJJisolationNN
r5fourCDPVsNNS
r5lowJJincidenceNN

#Rule:N-HeadNoun
r8radiofrequencyNNablationNN
r8irrigated-tipNNcatheterNN

#Rule:HeadNoun-V
r11ablationNNallowsVBZ
r11PVOrganizationAnnotationusingVBG

#Rule:V-HeadNoun
r21usingVBGcatheterNN
r21allowsVBZisolationNN

#Rule:PPinNP
r26ablationNNofINPVOrganizationAnnotation
r26catheterNNinINpatientsNNS
r26patientsNNSwithINfibrillationNN
r26isolationNNofINPVsNNS
r26incidenceNNofINstenosisNN

#Rule:PPinVP
r30allowsVBZwithINincidenceNN

@lemmas-left	guide	limited	using	<40	Irrigated-Tip	treatment	2003	noted	higher	36	PVI	showed	free	compared	movement	flutter	systematic	points	option	pacing	function.	PVs	%	feasible	thoughts:1	suggest	tricuspid	further	observed	1	system	Reablation	aim	6	coronary	quality	EF	low	introduction	we	Methods	use	date	symptomatic	January	life	patient	Introduction	significant	Complication	assess	isthmus	RESULTS	left	procedure	man	irrigated-tip	impaired	induce	rates	taking	up	10	ef	including	remain	background	p	Tip	QoL	December	2000	methods	annulus	Moderate	change	normal	perform	splitting	ninety-four	has	Catheter Ablation of Atrial Fibrillation	antiarrhythmic	angiography	consisted	comprised	paroxysmal	81	consequence	87	had	assessed	be	67	66	control	narrowing	efficacy	Ninety-four	size	december	PV	stasis	crista	AF	require	comprise	73	0.03	catheter	wavefronts	AF-free	disparate	result	therapeutic	136	CONCLUSIONS	ejection	following	complete	Randomized	four	men	multiple	population	sample	49	protocol	requirement	fraction	systolic	fibrillation	nonsignificant	nonrandomized	outcomes	complication	months	complications	school	take	there	52	increase	circuit	pv	54	our	50	LV	ablation	determine	avoiding	reentrant	tip	283	sufficient	avoid	are	initial	undergo	randomized	conduction	0.7	limit	atrial	drugs	reablation	METHODS	warranted.2	compare	dominant	endpoint	include	many	present	atrial fibrillation	gaps	recurrence	performed	ever-changing	month	conclusion	Cavotricuspid isthmus	years	delivery	impair	gap	different	evaluate	creation	subject	lv	block	mapping	cavotricuspid isthmus	bidirectional	remaining	Pulmonary vein	patients	109	three-fourths	clinical	99	100	note	end	aimed	drug-refractory	pvs	[EF]	refractory	consecutive	OBJECTIVES	unknown	outcome	pvi	electrophysiologic	undergoing	point	persistent	underwent	improvement	method	Systematic	circumferential	End	old	selective	subjects	stenosis	study	show	studies	procedures	function	were	more	results	january	atrial fibrillation (AF	age	..	PV stenosis	three	fusion	74-year-old	required	objective	BACKGROUND	consist	Mean EF	noncontact	Conclusion	sinus	noninducible	follow-up	377	Results	included	Bidirectional	Followings	other	ventricular	allow	have	one	PV diameter	radiofrequency	achieve	cavotricuspid	requirements	vein	was	risk	controls	achieved	guided	rate	allows	isolation	Catheter	induced	mean	incidence	drug	wavefront	5.3	moderate	veins	4.6	safety	observe	pulmonary	Con	terminalis	group	remained	energy	6-month	changes	
@lemmas-right	guide	limited	they	LV	using	ablation	treatment	determine	higher	avoiding	showed	PVI	avoid	free	are	flutter	undergo	movement	points	conduction	option	pacing	limit	function.	PVs	%	suggest	endpoint	include	atrial fibrillation	gaps	system	recurrence	aim	performed	month	EF	years	delivery	impair	low	8.8	gap	creation	subject	use	block	lv	cavotricuspid isthmus	mapping	date	14	January	patients	patient	life	assess	procedure	man	aimed	pvs	[EF]	impaired	induce	rates	unknown	outcome	pvi	taking	undergoing	point	ef	remain	p	underwent	improvement	Tip	method	QoL	December	methods	annulus	subjects	stenosis	show	perform	study	studies	procedures	function	were	Catheter Ablation of Atrial Fibrillation	results	angiography	january	atrial fibrillation (AF	consisted	age	PV stenosis	consequence	had	assessed	primarily	be	control	consist	Mean EF	size	noninducible	follow-up	december	PV	AF	included	catheter	wavefronts	result	Followings	allow	have	Yet	PV diameter	CONCLUSIONS	achieve	requirements	was	risk	controls	guided	following	rate	allows	isolation	induced	mean	incidence	men	population	protocol	requirement	wavefront	fibrillation	veins	complication	outcomes	months	complications	school	safety	take	Con	terminalis	increase	circuit	group	remained	
@lemmas-center	to	with	for	at	through	without	in	around	while	after	of	over	during	between	